Management of SLE During Pregnancy
The most appropriate treatment is antimalarial drugs (hydroxychloroquine) and low-dose aspirin (Option C), which forms the foundation of SLE management during pregnancy and should be continued or initiated in all pregnant women with SLE unless contraindicated.
Core Treatment Strategy
Hydroxychloroquine (HCQ) - The Cornerstone
Both the 2020 ACR and 2017 EULAR guidelines strongly recommend that all women with SLE take hydroxychloroquine during pregnancy 1, 2. The evidence is compelling:
- If already taking HCQ: strongly recommend continuing it during pregnancy
- If not taking HCQ: conditionally recommend starting it if no contraindication exists
- Multiple studies demonstrate maternal and pregnancy benefits with low risk to mother and fetus 1
- HCQ is extensively used and beneficial for improving pregnancy outcomes 3
Low-Dose Aspirin - Essential Prophylaxis
All pregnant women with SLE should receive low-dose aspirin (81-100 mg daily) beginning in the first trimester 1, 2. This recommendation is based on:
- SLE patients are at high risk for preeclampsia
- Aspirin prophylaxis is particularly important in those with lupus nephritis or positive antiphospholipid antibodies
- Should be started at the end of the first trimester 4, 5
Why Other Options Are Inappropriate
Option A (High-dose steroids) - INCORRECT
While oral glucocorticoids can be used to prevent or manage SLE flares during pregnancy 2, high-dose steroids are not first-line management. Glucocorticoids should be limited to the lowest effective dose 4, 5. High-dose steroids are reserved for moderate-to-severe flares, not routine management.
Option B (Methotrexate) - CONTRAINDICATED
Methotrexate is absolutely contraindicated in pregnancy 2, 4, 5. It is known to be teratogenic and must be avoided. This is explicitly stated in all major guidelines.
Option D (Immunosuppressive therapy only) - INCOMPLETE
While immunosuppressives like azathioprine, tacrolimus, and cyclosporine can be used during pregnancy 2, 5, they are not first-line therapy. They are used when needed to control disease activity, but the foundation remains HCQ plus low-dose aspirin.
Additional Management Considerations
Disease Activity Monitoring
- Monitor SLE disease activity at least once per trimester with clinical history, examination, and laboratory tests 1
- Check complete blood count, urinalysis, urinary protein:creatinine ratio, anti-DNA, C3, and C4 levels 1
- Assess renal function parameters and serological markers (serum C3/C4, anti-dsDNA titres) 2
Antiphospholipid Antibody Testing
- Test for lupus anticoagulant, anticardiolipin, and anti-β2GPI antibodies once before or early in pregnancy 1
- If positive for antiphospholipid syndrome: add therapeutic anticoagulation (heparin) to low-dose aspirin 2
Safe Immunosuppressives When Needed
If disease control requires additional therapy beyond HCQ and aspirin:
- Safe options: Azathioprine, tacrolimus, cyclosporine 2, 5
- Contraindicated: Mycophenolate mofetil/mycophenolic acid, methotrexate, leflunomide, cyclophosphamide 2, 4, 5
Critical Pitfalls to Avoid
- Never discontinue HCQ during pregnancy - this increases flare risk significantly
- Never use methotrexate - it is teratogenic
- Do not delay aspirin - start by end of first trimester to prevent preeclampsia
- Avoid high-dose steroids as routine management - use lowest effective dose only when needed for flares
Answer: C. Antimalarial drugs and low-dose aspirin